Helius Medical Approves Reverse Stock Split and Share Increase

Helius Medical Technologies ( (HSDT) ) has provided an announcement.

At a special meeting on May 23, 2025, Helius Medical Technologies‘ stockholders approved several significant proposals, including a reverse stock split and an increase in authorized shares to 800 million. These decisions aim to ensure compliance with Nasdaq listing requirements and facilitate potential financing, impacting the company’s operational and strategic positioning.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Spark’s Take on HSDT Stock

According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.

Helius Medical Technologies faces significant financial hurdles with declining revenue and consistent losses, impacting both cash flow and equity. Technical indicators show a weak momentum with a slight bearish trend. Valuation metrics reflect unprofitability, making the stock less attractive. Immediate improvements in financial performance and operational efficiency are crucial for a positive outlook.

To see Spark’s full report on HSDT stock, click here.

More about Helius Medical Technologies

Helius Medical Technologies operates in the medical technology industry, focusing on developing non-invasive platform technologies for the treatment of neurological symptoms caused by disease or trauma.

Average Trading Volume: 12,414

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.33M

See more data about HSDT stock on TipRanks’ Stock Analysis page.